ReviewGynecology and pelvic medicine2025
Application progress of radiofrequency (RF) therapy in pelvic floor disorders (PFDs): a narrative review focusing on randomized controlled trials.
Review in Gynecology and pelvic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of bipolar radiofrequency in the treatment of vaginal laxity: a single-center cohort study in premenopausal women.Lasers in medical science · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: The application of radiofrequency (RF) therapy in pelvic floor disorders (PFDs) has been on the rise. However, its efficacy and safety remain a subject of debate. This narrative review aims to synthesize the current evidence from randomized controlled trials (RCTs) on the application of RF therapy in PFDs, including vaginal laxity syndrome (VLS), stress urinary incontinence (SUI), chronic pelvic pain (CPP), and fecal incontinence (FI). This narrative review was conducted to synthesize the current evidence on the application of RF therapy in PFDs, with a specific focus on RCTs to ensure the robustness and reliability of the included evidence. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus covering the period from January 2002 to July 2025. RCTs investigating the efficacy, safety, and mechanisms of RF therapy in PFDs were included. Non-randomized studies and reviews were referenced for contextual support but not as primary evidence. Key Content and Findings: RF technology, a non-invasive/minimally invasive energy-based modality, shows potential in managing PFDs. For VLS, limited RCTs confirm its efficacy in improving symptoms and sexual function with good safety, though treatment protocols and efficacy duration need further study. In SUI, RF works as an effective adjunct to pelvic floor muscle training, but its standalone efficacy and comparison with other modalities require more high-quality research. For CPP and FI, RF's efficacy and safety remain controversial, lacking sufficient evidence-based support for widespread use, with relevant guidelines not recommending it currently. Conclusions: Overall, the application of RF therapy in PFDs is still in the exploratory stage, with numerous unresolved issues such as inconsistent treatment parameters, short follow-up periods, small sample sizes, and a predominance of single-center studies. Future research should focus on designing rigorous multi-center, large-sample RCTs, optimizing treatment protocols, clarifying the mechanisms of action, establishing scientific efficacy evaluation systems, and conducting stratified analyses based on individual differences. This will promote the precise, safe, and effective application of RF therapy in PFDs, providing more high-quality treatment options for patients with PFDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.